$COO

Keel Paul A purchased $250K of COO

Keel Paul A purchased 4,701 shares of COOPER COMPANIES, INC. (COO) at $53.18 ($0.25M total) on 2026-09-11.

Original reporting
SEC EDGAR · Keel Paul A
Published Sep 15, 2026, 8:46 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 15, 2026, 8:56 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$COO
Neutral
medium confidence
Mentioned
$COO
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$COONeutralLow
01

Why it matters

The Form 4 filing provides the first public disclosure of this insider purchase, but the amount is modest.

02

Market read

A routine insider buy with limited trading relevance; may be noted by quantitative insiders but unlikely to drive price.

03

What to watch

Potential upcoming product launches or contract wins not disclosed could make the buy more meaningful.

Relevance 5/10Novelty 4/10Timing: filed Sep 15 2026

Background

Cooper Companies, Inc. (COO) is a medical device and health‑care services firm listed on NYSE.

Company-level read

Ticker impact

$COONeutralMedium confidence
Context

Director Keel Paul A purchased 4,701 COO shares at $53.18, total $250K on Sep 11, 2026.

Expected impact

Minimal short‑term price effect; may provide slight upside bias.

Evidence & confidence

Purchase amount is under $1M and represents a tiny fraction of outstanding shares, limiting market impact.

Market effects

Insider activity in healthcare distribution sector is routine; no broader sector shift.

Limited to US investors tracking COO; no regional ripple.

Negligible global impact.

Counterpoint

The purchase could be a window‑dressing move rather than genuine confidence.

Key entities

  • Cooper Companies, Inc.

    Issuer of the shares purchased.

  • Keel Paul A

    Director of COO who made the purchase.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$COOMedAI 8/10

A Failed Auction and a 15% Drop: Is Cooper Companies (COO) a Value Trap or a Bargain?

Cooper Companies (COO) ended its 9-month effort to sell CooperSurgical after bids undervalued the business, according to management. The stock dropped 15% to a 52-week low near $51 after a Q3 miss and cut outlook. The company's core contact lens business, CooperVision, posted flat organic revenue growth, contributing to the guidance cut. Management authorized a $1B share repurchase program, while Bank of America questioned the valuation. COO reported record Q3 free cash flow of $273M.

$COOMedAI 8/10

The Cooper Companies (COO) Faces Near-Term Pressure from Slowing Contact Lens Demand

The Cooper Companies (COO) lowered its fiscal 2026 profit and revenue forecasts due to weaker-than-expected contact lens demand, with adjusted EPS now expected at $4.51–$4.55 and revenue at $4.23–$4.25 billion. Q3 revenue was $1.07 billion, missing estimates, though adjusted EPS beat at $1.15. The company cited U.S. channel inventory reductions as a key factor and decided to retain CooperSurgical.